India, July 16 -- Shares of Qualigen Therapeutics, Inc. (QLGN) jumped 20 on Tuesday after the company announced significant progress in expanding the global patent coverage of its lead cancer drug candidate, QN-302.
The stock opened sharply higher at $5.49, up from the previous close of $3.53. Trading volume was over 44 million shares, far above average of 23,000.
Qualigen announced that it has been granted new patents across more than 25 countries, covering both the composition and manufacturing methods of QN-302. The patents, titled "Substituted Naphthalene Diimides and Their Use," stem from work by Professor Stephen Neidle and his team at University College London and are licensed exclusively to Qualigen.
googletag.cmd.push(function()...